Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011

LONDON, 30 October 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Aura Biosciences (“Aura”), a leader in the development of novel targeted therapies in ocular oncology, has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of lightactivated AU-011, its lead product candidate for the primary treatment of choroidal melanoma.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...